CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology corporate pioneering the advance of a brand new category of programmable epigenetic mRNA drugs, nowadays introduced that it’ll provide a trial-in-progress poster on the upcoming American Society for Scientific Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), happening in San Francisco, Calif., and nearly, January 19–21, 2023. The poster will spotlight the design of the continued MYCHELANGELO™ I learn about, a Section 1/2 open-label trial comparing OTX-2002, a first-in-class Omega Epigenomic Controller™ (OEC) candidate, for the remedy of hepatocellular carcinoma (HCC) and different forged tumor varieties recognized for affiliation with the c-Myc (MYC) oncogene.
Main points for the ASCO Gastrointestinal Cancers Symposium Trial-in-Development poster presentation are as follows:
Name: A segment 1/2 open-label learn about to guage the protection, tolerability, pharmacokinetics, pharmacodynamics, and initial antitumor process of OTX-2002 as a unmarried agent and together with usual of care in sufferers with hepatocellular carcinoma and different forged tumor varieties recognized for affiliation with the MYC oncogene (MYCHELANGELO I).
Summary #: TPS627
Consultation Data: Trials-in-Development Poster Consultation B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Location: Stage 1, West Corridor, Poster N16
Date and Time: Friday, January 20, 2023, from 12:00-1:30 p.m. PST and four:30-5:30 p.m. PST
The poster can be made to be had at the Omega site at https://omegatherapeutics.com/our-science/#publications-research concurrently the presentation.
OTX-2002 is a first-in-class Omega Epigenomic Controller™ in building for the remedy of hepatocellular carcinoma (HCC). OTX-2002 is an mRNA healing delivered by the use of lipid nanoparticles (LNPs) and is designed to downregulate MYC expression pre-transcriptionally via epigenetic modulation whilst probably overcoming MYC autoregulation. MYC is a grasp transcription issue that regulates cellular proliferation, differentiation and apoptosis and performs an important position in additional than 50% of all human cancers. OTX-2002 is these days being evaluated within the Section 1/2 MYCHELANGELO™ I trial in sufferers with relapsed or refractory HCC and different forged tumor varieties recognized for affiliation with the MYC oncogene; seek advice from clinicaltrials.gov (NCT05497453) for extra main points.
About Omega Therapeutics
Omega Therapeutics, based via Flagship Pioneering, is a clinical-stage biotechnology corporate pioneering the advance of a brand new category of programmable epigenetic mRNA drugs. The Corporate’s OMEGA platform harnesses the ability of epigenetics, the mechanism that controls gene expression and each side of an organism’s existence from cellular genesis, enlargement, and differentiation to cellular demise. The usage of a collection of applied sciences, paired with Omega’s means of systematic, rational, and integrative drug design, the OMEGA platform allows keep watch over of basic epigenetic processes to proper the foundation reason behind illness via returning aberrant gene expression to a regular vary with out changing local nucleic acid sequences. Omega’s modular and programmable mRNA drugs, Omega Epigenomic Controllers™, goal explicit epigenomic loci inside of insulated genomic domain names, EpiZips, from among 1000’s of distinctive, mapped, and validated genome-wide DNA-sequences, with prime specificity to durably music unmarried or a couple of genes to regard and remedy sicknesses via remarkable precision epigenomic keep watch over. Omega’s pipeline of building applicants span a spread of illness spaces, together with oncology, regenerative medication, multigenic sicknesses together with immunology, and choose monogenic sicknesses.
For more info, seek advice from omegatherapeutics.com, or apply us on Twitter and LinkedIn.
Ahead-Having a look Statements
This press unlock incorporates forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995. All statements contained on this press unlock that don’t relate to issues of ancient reality must be regarded as forward-looking statements, together with with out limitation statements in regards to the timing and design of our Section 1/2 MYCHELANGELOTM I scientific trial; the possibility of the OMEGA platform to engineer programmable epigenetic mRNA therapeutics that effectively control gene expression via focused on insulated genomic domain names; expectancies surrounding the possibility of our product applicants, together with OTX-2002; and expectancies relating to our pipeline, together with trial design, initiation of preclinical research and development of a couple of preclinical building techniques in oncology, immunology, regenerative medication, and choose monogenic sicknesses. Those statements are neither guarantees nor promises, however contain recognized and unknown dangers, uncertainties and different essential components that can reason our precise effects, efficiency or achievements to be materially other from any long run effects, efficiency or achievements expressed or implied via the forward-looking statements, together with, however now not restricted to, the next: the unconventional generation on which our product applicants are primarily based makes it tough to expect the time and value of preclinical and scientific building and due to this fact acquiring regulatory approval, if in any respect; the considerable building and regulatory dangers related to epigenomic controller machines because of the unconventional and remarkable nature of this new class of medications; our restricted working historical past; the incurrence of important losses and the truth that we predict to proceed to incur vital further losses for the foreseeable long run; our want for considerable further financing; our investments in examine and building efforts that additional beef up the OMEGA platform, and their affect on our effects; uncertainty relating to preclinical building, particularly for a brand new category of medications comparable to epigenomic controllers; doable delays in and unexpected prices bobbing up from our scientific trials; the truth that our product applicants is also related to critical hostile occasions, unwanted uncomfortable side effects or produce other homes that would halt their regulatory building, save you their regulatory approval, prohibit their business doable, or lead to vital damaging penalties; the affect of greater call for for the manufacture of mRNA and LNP primarily based vaccines to regard COVID-19 on our building plans; difficulties production the unconventional generation on which our OEC applicants are primarily based; our skill to conform to fast and important technological trade; our reliance on 3rd events for the manufacture of fabrics; our skill to effectively gain and identify our personal production amenities and infrastructure; our reliance on a restricted selection of providers for lipid excipients utilized in our product applicants; our skill to advance our product applicants to scientific building; and our skill to acquire, take care of, implement and adequately give protection to our highbrow assets rights. Those and different essential components mentioned beneath the caption “Chance Elements” in our most up-to-date Quarterly Document on Shape 10-Q and our Annual Document on Shape 10-Okay for the 12 months ended December 31, 2021, and our different filings with the SEC, may just reason precise effects to vary materially from the ones indicated via the forward-looking statements made on this press unlock. Such a forward-looking statements constitute control’s estimates as of the date of this press unlock. Whilst we would possibly elect to replace such forward-looking statements one day someday, we disclaim any legal responsibility to take action, although next occasions reason our perspectives to modify.
CONTACT: CONTACT Investor touch: Eva Stroynowski Omega Therapeutics 617.949.4370 [email protected] Media touch: Jason Braco LifeSci Communications 646.751.4361 [email protected]